Phase 4
Completed N=40
Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
Source: ClinicalTrials.gov NCT00746395 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcomePrimary: Complete Small Bowel Transit — 75; 95 percentage of subjects with passage
◆ Published Evidence
Established
38citations · ~2 / year
Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study.
Summary
This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy.
Linked Publications
-
Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Small Bowel Transit |
75; 95 | — |
| SECONDARY Small Bowel Transit |
188.1; 218.9 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers
Exclusion Criteria
- Gi disorders, gi surgery, cardiac, renal, or hepatic insufficiency, severe diarrhea
Data sourced from ClinicalTrials.gov (NCT00746395) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.